Cullinan Therapeutics, Inc., a biopharmaceutical company specializing in modality-agnostic targeted therapies, has announced a new partnership with Genrix Bio. Under the agreement, Cullinan will pay an upfront license fee of $20 million for exclusive global rights, excluding Greater China, to develop and commercialize velinotamig, a BCMAxCD3 bispecific T cell engager. This collaboration aims to advance Cullinan's leadership in T cell engager development for autoimmune diseases, adding to their pipeline that already includes a CD19 TCE. Genrix Bio stands to receive up to $292 million in development and regulatory milestones, an additional $400 million in sales-based milestones, and tiered royalties from mid-single digits to mid-teens on potential net sales outside Greater China. Cullinan's strengthened portfolio positions them to address a broader range of diseases while maintaining financial resources into 2028.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。